PAR — Paradigm Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$155.77m
- AU$138.96m
- AU$7.11m
- 55
- 16
- 55
- 36
Annual cashflow statement for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.26 | 0.048 | 0.95 | 0.846 | 0.342 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -34.9 | -32.2 | -45.2 | -65.9 | -16 |
| Capital Expenditures | -0.032 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.7 | 0 | 0 | — | 0.046 |
| Change in Net Investments | |||||
| Cash from Investing Activities | 0.668 | 0 | 0 | — | 0.046 |
| Financing Cash Flow Items | 0.104 | 0.205 | -3.35 | -1.84 | -0.882 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1 | 0.07 | 62.5 | 28.2 | 15 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -32.9 | -31.4 | 16.7 | -38.5 | -1 |